A number of other analysts have also recently weighed in on the company. ValuEngine cut Amgen from a hold rating to a sell rating in a research report on Tuesday, May 26th. Mizuho reaffirmed a hold rating and set a $215.00 price target on shares of Amgen in a research report on Thursday, April 30th. Piper Sandler lifted their price target on Amgen from $235.00 to $255.00 and gave the stock an overweight rating in a research report on Thursday, April 30th. Zacks Investment Research raised Amgen from a hold rating to a buy rating and set a $240.00 price target for the company in a research report on Wednesday, April 15th. Finally, Oppenheimer assumed coverage on Amgen in a research report on Friday, May 1st. They set a buy rating and a $252.00 price target for the company. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and eighteen have assigned a buy rating to the stock. Amgen has a consensus rating of Buy and an average target price of $245.85.
Amgen stock opened at $235.86 on Friday. The company has a debt-to-equity ratio of 3.16, a current ratio of 1.59 and a quick ratio of 1.28. The stock has a market capitalization of $136.97 billion, a price-to-earnings ratio of 18.48, a PEG ratio of 1.99 and a beta of 0.94. Amgen has a 1-year low of $173.12 and a 1-year high of $244.99. The business has a fifty day moving average price of $229.23 and a 200-day moving average price of $225.31.
In related news, Director Ronald D. Sugar sold 1,000 shares of Amgen stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $233.35, for a total value of $233,350.00. Following the completion of the transaction, the director now owns 15,636 shares in the company, valued at approximately $3,648,660.60. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director R Sanders Williams sold 425 shares of Amgen stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $237.31, for a total value of $100,856.75. Following the completion of the transaction, the director now owns 5,834 shares of the company’s stock, valued at approximately $1,384,466.54. The disclosure for this sale can be found here. In the last 90 days, insiders sold 3,425 shares of company stock valued at $792,017. 0.36% of the stock is owned by company insiders.
A number of hedge funds have recently bought and sold shares of AMGN. Wealth Quarterback LLC acquired a new stake in Amgen in the 4th quarter worth about $3,116,210,000. Norges Bank acquired a new stake in Amgen in the 4th quarter worth about $1,515,191,000. Clearbridge Investments LLC boosted its holdings in Amgen by 151.2% in the 1st quarter. Clearbridge Investments LLC now owns 4,118,757 shares of the medical research company’s stock worth $834,996,000 after buying an additional 2,478,922 shares during the last quarter. Capital Research Global Investors boosted its holdings in Amgen by 5.2% in the 4th quarter. Capital Research Global Investors now owns 35,337,639 shares of the medical research company’s stock worth $8,518,844,000 after buying an additional 1,743,084 shares during the last quarter. Finally, APG Asset Management N.V. boosted its holdings in Amgen by 298.8% in the 1st quarter. APG Asset Management N.V. now owns 1,741,626 shares of the medical research company’s stock worth $294,673,000 after buying an additional 1,304,921 shares during the last quarter. Institutional investors own 75.75% of the company’s stock.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Read More: Are sell-side analysts objective?
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.